Analysts Set Tocagen Inc (TOCA) Price Target at $17.83

Shares of Tocagen Inc (NASDAQ:TOCA) have earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $17.83.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research cut Tocagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 9th. HC Wainwright assumed coverage on Tocagen in a report on Monday. They issued a “buy” rating and a $14.50 price target on the stock. B. Riley assumed coverage on Tocagen in a report on Wednesday, May 16th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, BidaskClub upgraded Tocagen from a “hold” rating to a “buy” rating in a report on Saturday, March 17th.

Shares of TOCA traded down $0.12 on Monday, reaching $9.62. The stock had a trading volume of 400 shares, compared to its average volume of 118,474. The stock has a market cap of $191.95 million, a P/E ratio of -3.60 and a beta of 2.43. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.56 and a quick ratio of 4.56. Tocagen has a twelve month low of $8.60 and a twelve month high of $15.50.

Tocagen (NASDAQ:TOCA) last released its quarterly earnings results on Thursday, May 10th. The company reported ($0.65) earnings per share for the quarter. The firm had revenue of $0.01 million during the quarter. Tocagen had a negative return on equity of 57.09% and a negative net margin of 109,579.49%. research analysts expect that Tocagen will post -1.56 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in the business. Teachers Advisors LLC grew its holdings in Tocagen by 40.7% during the 4th quarter. Teachers Advisors LLC now owns 21,163 shares of the company’s stock valued at $217,000 after buying an additional 6,120 shares during the last quarter. American International Group Inc. grew its holdings in Tocagen by 112.9% during the 4th quarter. American International Group Inc. now owns 11,995 shares of the company’s stock valued at $123,000 after buying an additional 6,362 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Tocagen during the 4th quarter valued at $122,000. Geode Capital Management LLC grew its holdings in Tocagen by 16.0% during the 4th quarter. Geode Capital Management LLC now owns 90,452 shares of the company’s stock valued at $927,000 after buying an additional 12,472 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its holdings in Tocagen by 58.4% during the 4th quarter. TIAA CREF Investment Management LLC now owns 35,994 shares of the company’s stock valued at $369,000 after buying an additional 13,267 shares during the last quarter. Hedge funds and other institutional investors own 32.26% of the company’s stock.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit